Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KIO-301
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Kiora Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KIO-301 acts as a reversible 'photoswitch', specifically designed to restore the eyes' ability to perceive and interpret light in visually impaired patients with retinitis pigmentos.
Brand Name : KIO-301
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2023
Lead Product(s) : KIO-301
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Kiora Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?